Current therapy for hepatitis C: pegylated interferon and ribavirin - 31/08/11
Doi : 10.1016/S1089-3261(02)00077-6
John G McHutchison, MD a, Michael W Fried, MD ⁎, b
a Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA
b Division of Digestive Diseases, University of North Carolina at Chapel Hill, Room 708, Chapel Hill CB #7080, 1111 Bioinfomatics Building, Chapel Hill, NC 27599-7080, USA
*Corresponding author. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA
Plan
 | Dr. McHutchison has received reasearch support from Schering Plough and Roche and is a member of the speakers bureau for both companies. Dr McHutchison has also acted as a consultant and advisor from Schering Plough. Dr. Fried is funded in part by RO-I HL64817-01. Dr. Fried receives research support from Hoffman-LaRoche and Schering |
© 2003
Elsevier Science (USA). Tous droits réservés.
Vol 7 - N° 1
P. 149-161 - février 2003 Retour au numéro
Article précédent
- Pegylated interferons
- Umaprasanna S Karnam, K.Rajender Reddy
- Mathematical modeling of viral kinetics: a tool to understand and optimize therapy
- Thomas J Layden, Jennifer E Layden, Ruy M Ribeiro, Alan S Perelson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?